Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for MASH/NASH and Oncology Biomarker Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KRT18 drug discovery and biomarker assay development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRT18 Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View KRT18 Products |
| Cleaved Antigen | KRT18 Caspase-Cleaved Fragment (Asp396) Truncated recombinant protein representing the M30 apoptotic neo-epitope. High purity (>95%). |
View KRT18 Products |
| Gene Delivery | KRT18 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to evaluate intracellular intermediate filament dynamics. |
View KRT18 Products |
| Benchmark Ab | Anti-KRT18 Recombinant Antibody (M30/M65 Biosimilars) Recombinant positive control antibodies targeting the caspase-cleaved or total KRT18 epitopes. |
View KRT18 Products |
| Validator | KRT18 siRNA Set For knockdown verification in epithelial tumor models and functional assays. |
View KRT18 Products |
| Related Target A | KRT8 (Keratin 8) Primary dimerization partner of KRT18; critical for intermediate filament assembly and stability. |
View KRT8 Products |
| Related Target B | KRT19 (Keratin 19) Co-expressed epithelial marker used in combination panel assays for carcinoma differentiation. |
View KRT19 Products |
| Related Target C | Caspase-3 The primary executioner protease responsible for cleaving KRT18 at Asp396 to generate the M30 biomarker. |
View Caspase-3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiation of apoptotic (M30) vs. necrotic (M65) KRT18 pathways | Precisely engineered full-length and caspase-cleaved (Asp396) recombinant protein fragments available with >95% purity. |
| Cross-reactivity with homologous keratins (e.g., KRT8, KRT19) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment to ensure assay specificity. |
| Lack of standardized clinical assay calibrators | Recombinant Clinical Benchmark Antibodies (M30 and M65 clones) included for reliable assay calibration. |
| Matrix interference in serum/plasma ELISA development | Endotoxin-controlled, low-aggregation recombinant protein standards optimized for complex matrix recovery. |
Live Cytokeratin 18/KRT18 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of Cytokeratin 18 (KRT18) is expanding rapidly, transitioning from a classic epithelial tumor biomarker to a critical pharmacodynamic (PD) and diagnostic endpoint in metabolic liver diseases. Specifically, in Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH), the FDA approval of thyroid hormone receptor-beta (THR-β) agonists and the clinical progression of FGF21 analogs have cemented caspase-cleaved KRT18 (M30) and total KRT18 (M65) as gold-standard non-invasive biomarkers for monitoring hepatocyte apoptosis and necrosis.
In oncology, KRT18 serves as a vital liquid biopsy marker for circulating tumor cells (CTCs) and treatment-induced cell death (apoptosis) in epithelial cancers, including breast, prostate, colorectal, and non-small cell lung cancer (NSCLC). As therapeutic modalities shift toward targeted therapies, antibody-drug conjugates (ADCs), and combination regimens, the demand for highly specific KRT18 quantitative assays has intensified to accurately track real-time drug efficacy and tissue toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| MASH Therapeutics (Small Mol/Biologics) | Madrigal, Akero, 89bio, Boehringer Ingelheim | MASH / NASH, Liver Fibrosis | Quantitative ELISA development (Requires highly stable full-length and cleaved KRT18 protein calibrators) |
| Oncology Diagnostics / CTC Assays | Menarini Silicon Biosystems, Roche, Abbott | Breast Cancer, Prostate Cancer, NSCLC | Specific epitope recognition (Requires sequence-verified KRT18 and KRT8 proteins for cross-reactivity screening) |
| Toxicology & DILI Screening | Major Pharma, CROs | Drug-Induced Liver Injury (DILI) | High-throughput multiplex assays (Requires endotoxin-controlled recombinant KRT18 and benchmark antibodies) |